Literature DB >> 12493146

The pathogenesis of neoplastic meningitis.

Morris D Groves1.   

Abstract

Neoplastic meningitis (NM) is a dreaded metastatic complication occurring in 5% to 10% of cancer patients. Survival is limited, usually ranging from 4 to 16 weeks. The pathogenesis of NM has not been extensively investigated but can be considered from the anatomic and molecular biologic standpoints. Malignant cells reach the cerebrospinal fluid (CSF) and meninges by direct invasion from tumors located near or within the central nervous system (CNS), or via the bloodstream or other pathways that contact the CNS. Symptoms of NM are caused by malignant cells invading and damaging nervous tissue, obstructing the vascular supply to nervous tissue, or obstructing CSF pathways. The molecular changes responsible for the development of NM are not well delineated, but it is likely that they involve changes in molecules responsible for tumor cell adhesion, migration, and proliferation. An understanding of the pathogenesis of NM will allow for its earliest possible diagnosis and ultimately lead to therapies targeted at the underlying molecular causes of this devastating condition.

Entities:  

Mesh:

Year:  2003        PMID: 12493146     DOI: 10.1007/s11912-003-0082-y

Source DB:  PubMed          Journal:  Curr Oncol Rep        ISSN: 1523-3790            Impact factor:   5.075


  44 in total

1.  Heparin and cancer revisited: mechanistic connections involving platelets, P-selectin, carcinoma mucins, and tumor metastasis.

Authors:  L Borsig; R Wong; J Feramisco; D R Nadeau; N M Varki; A Varki
Journal:  Proc Natl Acad Sci U S A       Date:  2001-03-13       Impact factor: 11.205

2.  Specific matrix metalloproteinase profiles in the cerebrospinal fluid correlated with the presence of malignant astrocytomas, brain metastases, and carcinomatous meningitis.

Authors:  M H Friedberg; M J Glantz; M S Klempner; B F Cole; G Perides
Journal:  Cancer       Date:  1998-03-01       Impact factor: 6.860

3.  The central nervous system in childhood leukemia. I. The arachnoid.

Authors:  R A Price; W W Johnson
Journal:  Cancer       Date:  1973-03       Impact factor: 6.860

4.  Quantitative relationships of intravascular tumor cells, tumor vessels, and pulmonary metastases following tumor implantation.

Authors:  L A Liotta; J Kleinerman; G M Saidel
Journal:  Cancer Res       Date:  1974-05       Impact factor: 12.701

5.  Intradural spinal metastases in patients with posterior fossa brain metastases from various primary cancers.

Authors:  R O Mirimanoff; N C Choi
Journal:  Oncology       Date:  1987       Impact factor: 2.935

6.  Vascular endothelial growth factor in CSF: a biological marker for carcinomatous meningitis.

Authors:  G Stockhammer; W Poewe; S Burgstaller; F Deisenhammer; A Muigg; S Kiechl; E Schmutzhard; H Maier; S Felber; P Schumacher; E Gunsilius; G Gastl
Journal:  Neurology       Date:  2000-04-25       Impact factor: 9.910

7.  Glioblastoma cells do not intravasate into blood vessels.

Authors:  J J Bernstein; C A Woodard
Journal:  Neurosurgery       Date:  1995-01       Impact factor: 4.654

8.  Meningeal carcinomatosis in head and neck cancer. Report of six cases and review of the literature.

Authors:  B G Redman; E Tapazoglou; M Al-Sarraf
Journal:  Cancer       Date:  1986-12-15       Impact factor: 6.860

9.  Diffuse involvement of the leptomeninges by tumour--a clinical and pathological study of 63 cases.

Authors:  R Boyle; M Thomas; J H Adams
Journal:  Postgrad Med J       Date:  1980-03       Impact factor: 2.401

10.  The relative roles of vitronectin receptor, E-selectin and alpha 4 beta 1 in cancer cell adhesion to interleukin-1-treated endothelial cells.

Authors:  R M Lafrenie; S Gallo; T J Podor; M R Buchanan; F W Orr
Journal:  Eur J Cancer       Date:  1994       Impact factor: 9.162

View more
  9 in total

1.  Neoplastic meningitis resulting from hematological malignancies: pharmacokinetic considerations and maximizing outcome.

Authors:  Jai Grewal; Marlon Saria; Harpreet K Grewal; Santosh Kesari
Journal:  Clin Investig (Lond)       Date:  2011-10

Review 2.  Biology and therapy of neoplastic meningitis.

Authors:  Aaron G Mammoser; Morris D Groves
Journal:  Curr Oncol Rep       Date:  2010-01       Impact factor: 5.075

Review 3.  Novel approaches to treating leptomeningeal metastases.

Authors:  Jai Grewal; Marlon Garzo Saria; Santosh Kesari
Journal:  J Neurooncol       Date:  2011-08-28       Impact factor: 4.130

4.  Biomarkers of disease: cerebrospinal fluid vascular endothelial growth factor (VEGF) and stromal cell derived factor (SDF)-1 levels in patients with neoplastic meningitis (NM) due to breast cancer, lung cancer and melanoma.

Authors:  Morris D Groves; Kenneth R Hess; Vinay K Puduvalli; Howard Colman; Charles A Conrad; Mark R Gilbert; Jeffrey Weinberg; Massimo Cristofanilli; W K Alfred Yung; Ta-Jen Liu
Journal:  J Neurooncol       Date:  2009-03-07       Impact factor: 4.130

5.  Neurological improvement of perineural and leptomeningeal spread of squamous cell carcinoma treated with intrathecal chemotherapy and systemic EGFR inhibition.

Authors:  Vincent Alexander van Vugt; Marlon Garzo Saria; Andres Javier; Navin Kesari; Tiffany Turpin; Santosh Kesari
Journal:  CNS Oncol       Date:  2017-10-06

6.  Neoplastic meningitis: How MRI and CSF cytology are influenced by CSF cell count and tumor type.

Authors:  P Prömmel; S Pilgram-Pastor; H Sitter; J-H Buhk; H Strik
Journal:  ScientificWorldJournal       Date:  2013-12-19

Review 7.  Leptomeningeal disease: current diagnostic and therapeutic strategies.

Authors:  Gautam Nayar; Tiffany Ejikeme; Pakawat Chongsathidkiet; Aladine A Elsamadicy; Kimberly L Blackwell; Jeffrey M Clarke; Shivanand P Lad; Peter E Fecci
Journal:  Oncotarget       Date:  2017-08-16

8.  Leptomeningeal Metastasis: The Role of Cerebrospinal Fluid Diagnostics.

Authors:  Lena Bönig; Nora Möhn; Jonas Ahlbrecht; Ulrich Wurster; Peter Raab; Wolfram Puppe; Kurt-Wolfram Sühs; Martin Stangel; Thomas Skripuletz; Philipp Schwenkenbecher
Journal:  Front Neurol       Date:  2019-08-20       Impact factor: 4.003

Review 9.  Recent Findings on Thymoquinone and Its Applications as a Nanocarrier for the Treatment of Cancer and Rheumatoid Arthritis.

Authors:  Ravi Raj Pal; Vasundhara Rajpal; Priya Singh; Shubhini A Saraf
Journal:  Pharmaceutics       Date:  2021-05-22       Impact factor: 6.321

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.